Clinical Trial Update: Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating a single dose of AVI-4126 (RESTEN-NG) in cerebrospinal fluid; the trial completed in individuals with neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• RESTEN-NG (AVI-4126)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED